妊娠及产后合并一线抗结核药物时依非韦伦的药代动力学
IMPAACT P1026s 前瞻性队列纳入 22 名 HIV 合并药物敏感结核孕妇,在妊娠中晚期及产后行 24 小时密集采血。晚孕期联用利福平/异烟肼时依非韦伦暴露低于产后,38% 未达目标 AUC0-24 或 Cmin;无结核组妊娠与产后暴露相似。建议加强病毒载量监测。
要点
- 晚孕期联用利福平/异烟肼时依非韦伦 AUC0-24 较产后低 19%。
- 38% 的合并结核孕妇未达到方案规定的 AUC0-24 或 Cmin 目标。
- 无结核孕妇妊娠期与产后依非韦伦暴露相似。
核心结论
- 晚孕期合并药物敏感结核治疗与依非韦伦暴露降低相关。
- 合并结核孕妇中 38% 未达到方案规定的 AUC0-24 或 Cmin 治疗目标。
- 无结核孕妇妊娠期与产后依非韦伦 AUC0-24 和 Cmax 相似。
研究设计与样本
- 前瞻性队列研究,纳入 22 名妊娠 20 至 37+6 周的 HIV 感染孕妇。
- 在妊娠中孕期、晚孕期及产后 2–8 周行稳态 24 小时密集药代动力学采样。
- 采用非房室分析计算 AUC0-24、Cmax、Cmin 和 CL/F,用几何均值比(GMR)及 90% CI 进行配对比较,α=0.10。
- 药代动力学结局与既往发表的无结核 HIV 感染孕妇队列比较,并对照方案规定的治疗目标。
主要发现
- 晚孕期与产后比较(n=13):AUC0-24 低 19%(GMR 0.81 [0.69-0.95];p=0.008)。
- 晚孕期与产后比较(n=13):Cmax 低 16%(GMR 0.84 [0.76-0.94];p=0.033)。
- 晚孕期与产后比较(n=13):Cmin 低 25%(GMR 0.75 [0.63-0.90];p=0.003)。
- 晚孕期与产后比较(n=13):CL/F 高 24%(GMR 1.24 [1.06-1.46];p=0.057)。
- 中孕期 GMR 方向与晚孕期相似但检验效能不足(中孕期与产后比较:n=4)。
关键数值与推荐
- 38% 的参与者未达到方案规定的 AUC0-24 或 Cmin 目标。
- 无结核组晚孕期与产后比较:AUC0-24 GMR 0.94 [0.86-1.02];p=0.373。
- 无结核组晚孕期与产后比较:Cmax GMR 1.07 [0.95-1.02];p=0.167。
- 中位依非韦伦浓度超过治疗阈值。
临床怎么用
- 对接受依非韦伦为基础抗逆转录病毒治疗并同时治疗结核病的 HIV 感染孕妇,建议频繁监测病毒载量。
- 晚孕期联用利福平/异烟肼时需关注依非韦伦暴露降低及未达治疗目标的风险。
- 无结核孕妇妊娠期依非韦伦暴露与产后相似,可参考常规监测策略。
局限性
- 中孕期与产后配对比较样本量小(n=4),检验效能不足。
- 依非韦伦暴露降低的临床意义尚不明确,需进一步研究。
- 随访期间未发生婴儿 HIV 感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Efavirenz (EFV) pharmacokinetics (PK) may be influenced by both pregnancy-related physiological changes and concurrent treatment for drug-sensitive tuberculosis (DS-TB), and intensive 24-h EFV PK data during rifampin (RIF)/ isoniazid (INH) treatment in pregnant women living with HIV (PWLHIV) and TB disease are lacking. We evaluated EFV PK in a prospective cohort of PWLHIV receiving WHO-recommended oral daily EFV alongside RIF and INH (with or without ethambutol [EMB] and pyrazinamide [PZA]). METHODS: Participants enrolled between 20 and 37+6 weeks gestation and underwent steady-state intensive 24-h PK sampling during second trimester (2T), third trimester (3T), and 2-8 weeks postpartum (PP) when eligible. PK parameters (AUC0-24, Cmax, Cmin and CL/F) were characterized using noncompartmental analysis, and paired comparisons across pregnancy stages were made using geometric mean ratios (GMR) with 90% confidence intervals (CI); α = 0.10. PK outcomes were compared with a previously published cohort of PWLHIV without TB and evaluated against protocol-defined therapeutic targets. RESULTS: Of 22 participants, PK data were available for 12, 21 and 13 participants in 2T, 3T and PP, respectively. In 3T (3T↔PP: n = 13), EFV exposure was lower than PP: AUC0-24 was 19% lower (GMR 0.81 [0.69-0.95]; p = 0.008), Cmax 16% lower (GMR 0.84 [0.76-0.94]; p = 0.033), Cmin 25% lower (GMR 0.75 [0.63-0.90]; p = 0.003), and apparent oral clearance (CL/F) 24% higher (GMR 1.24 [1.06-1.46]; p = 0.057). 2T GMRs were directionally similar to 3T but were underpowered (2T↔PP: n = 4). Although median EFV concentrations exceeded therapeutic thresholds, 38% of participants did not meet target AUC0-24 or Cmin. In contrast, in the non-TB group, the EFV AUC0-24 and Cmax were similar in pregnancy and postpartum (3T AUC0-24 GMR 0.94 [0.86-1.02]; p = 0.373 and Cmax GMR 1.07 [0.95-1. 02]; p = 0.167). No infants acquired HIV during follow-up. CONCLUSIONS: Late pregnancy combined with DS-TB treatment is associated with lower EFV exposure. Further investigation is needed to determine the clinical significance of these findings, but frequent viral load monitoring is advised in PWLHIV with TB disease receiving EFV-based antiretroviral treatment. GOV IDENTIFIER: NCT00042289. Pregnant women on both efavirenz-based antiretroviral treatment and tuberculosis treatment had lower efavirenz concentrations in the third trimester compared with postpartum and almost 40% of participants did not reach minimum target concentrations. Pregnant women without tuberculosis had the same efavirenz concentrations in pregnancy and postpartum. As the clinical implications are still unclear, it is advisable to evaluate viral suppression frequently when managing pregnant women on efavirenz and concurrent TB treatment.
引用
- Van Schalkwyk M, Wang J, Bekker A, et al. Pharmacokinetics of Efavirenz in Pregnancy and Postpartum with and Without First-line Tuberculosis Drugs: Results from IMPAACT P1026s. Clin Pharmacokinet. 2026. PMID: 42828638. doi:10.1007/s40262-026-01690-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。